Osama Kandalaft, MD
Internal Medicine · New Haven, CTNPI 1063868065
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 294 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,974 and has fallen 99.4% since, to $16 in 2025. Among internal medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$779
- AstraZeneca$569
- Novo Nordisk$439
- Lilly USA, LLC$406
- Astellas Pharma US Inc$328
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,82098%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,129 |
| GSK | 39 | $779 |
| AstraZeneca | 30 | $569 |
| Novo Nordisk | 24 | $439 |
| Lilly USA, LLC | 20 | $406 |
| Astellas Pharma US Inc | 11 | $328 |
| Exact Sciences | 13 | $283 |
| Amgen | 16 | $279 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $220 |
| Sumitomo Pharma America, Inc. | 9 | $213 |
| Bayer | 6 | $165 |
| Merck | 8 | $152 |
| Boehringer Ingelheim | 6 | $145 |
| Pfizer | 6 | $108 |
| Actelion Pharmaceuticals US, Inc. | 3 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $102 |
| Sunovion Pharmaceuticals Inc. | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $70 |
| Indivior Inc. | 2 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $53 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Braeburn Inc. | 1 | $25 |
| Watermark Medical, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Philips North America LLC | 1 | $14 |
How this compares
$5,919 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 143 | $143,401 |
| JardianceEmpagliflozin | 96 | $115,725 |
| OzempicSemaglutide | 99 | $107,005 |
| Repatha SureclickEvolocumab | 39 | $39,310 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $33,378 |
| GlyxambiEmpagliflozin/Linagliptin | 21 | $21,455 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $20,972 |
| MounjaroTirzepatide | 18 | $17,971 |
| GemtesaVibegron | 21 | $17,540 |
| RybelsusSemaglutide | 15 | $14,711 |
| EntrestoSacubitril/Valsartan | 14 | $12,894 |
| EliquisApixaban | 17 | $12,110 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $6,862 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,608 |
| VascepaIcosapent Ethyl | 12 | $3,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $569 | $145,913154 claims |
| Boehringer IngelheimJardiance, Glyxambi | $145 | $137,180117 claims |
| Novo NordiskOzempic, Rybelsus | $439 | $121,716114 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $779 | $38,98640 claims |
| MerckJanumet | $152 | $20,97218 claims |
| Lilly USA, LLCMounjaro | $406 | $17,97118 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $213 | $17,54021 claims |
| PfizerEliquis | $108 | $12,11017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in New Haven
- Nancy BrownNew Haven$1.6M
- Richard LiftonNew Haven$160K
- Wayne WarrenNew Haven$127K
- Marcella SmithNew Haven$66K
- Sanjay AggarwalNew Haven$54K
- Bubu BaniniNew Haven$39K
- Sandra SpringerNew Haven$39K
- Karen WangNew Haven$38K
- Michael SchilskyNew Haven$36K
- Kenechukwu MezueNew Haven$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.